Literature DB >> 24065519

EGCG suppresses Fused Toes Homolog protein through p53 in cervical cancer cells.

Sridhar Muthusami1, D S Prabakaran, Zhengzhe An, Jae-Ran Yu, Woo-Yoon Park.   

Abstract

The anticarcinogenic actions of epigallocatechin-3-gallate (EGCG), one of the main ingredients of green tea, against various cancer types including cervical cancer are well documented. Studies pertaining to the exact molecular mechanism by which EGCG induces cancer cell growth inhibition needs to be investigated extensively. In the present study, we observed a stupendous dose dependent reduction in the protein expression of Fused Toes Homolog (FTS) after treatment with EGCG at 1, 10, 25 and 50 μM. Further, we were interested in finding out whether the decrease in the protein expression of FTS was due to decreased mRNA synthesis. Real time reverse transcriptase polymerase chain reaction results revealed a similar dose dependent reduction in the FTS mRNA after EGCG treatment. Chromatin immunoprecipitation analysis revealed the interaction between p53 and the promoter region of FTS. A dose dependent increase in this interaction was evidenced at 25 and 50 μM EGCG treatment. p53 silencing increased the expression of FTS and also decreased the reduction in the levels of FTS expression after EGCG treatment. The decrease in the levels of FTS was more significant at 25 and 50 μM and is associated with reduced physical interaction of FTS with Akt, phosphorylation of Akt and survival of HeLa cells. Collectively, these results conclude that EGCG induced anti-proliferative action in the cervical cancer cell involves reduced mRNA expression of FTS through p53.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065519     DOI: 10.1007/s11033-013-2660-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

1.  Fused Toes Homolog modulates radiation cytotoxicity in uterine cervical cancer cells.

Authors:  Arunkumar Anandharaj; Senthilkumar Cinghu; Won-Dong Kim; Jae-Ran Yu; Woo-Yoon Park
Journal:  Mol Biol Rep       Date:  2011-03-20       Impact factor: 2.316

2.  PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53.

Authors:  Cheol-Hee Yoon; Eun-Soo Lee; Dae-Seog Lim; Yong-Soo Bae
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-24       Impact factor: 11.205

3.  EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.

Authors:  Masahito Shimizu; Atsuko Deguchi; Andrew K Joe; Judith F Mckoy; Hisataka Moriwaki; I Bernard Weinstein
Journal:  J Exp Ther Oncol       Date:  2005

Review 4.  Modulation of signal transduction by tea catechins and related phytochemicals.

Authors:  Masahito Shimizu; I Bernard Weinstein
Journal:  Mutat Res       Date:  2005-06-29       Impact factor: 2.433

5.  Apoptosis of human fibrosarcoma HT-1080 cells by epigallocatechin-3-O-gallate via induction of p53 and caspases as well as suppression of Bcl-2 and phosphorylated nuclear factor-κB.

Authors:  Mi Hee Lee; Dong-Wook Han; Suong-Hyu Hyon; Jong-Chul Park
Journal:  Apoptosis       Date:  2011-01       Impact factor: 4.677

Review 6.  Beneficial effects of green tea--a review.

Authors:  Carmen Cabrera; Reyes Artacho; Rafael Giménez
Journal:  J Am Coll Nutr       Date:  2006-04       Impact factor: 3.169

7.  Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line.

Authors:  Woo-Sik Jeong; In-Wha Kim; Rong Hu; Ah-Ng Tony Kong
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

8.  The tea polyphenol, (-)-epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines.

Authors:  Masatoshi Yokoyama; Mitsuyo Noguchi; Yoshifumi Nakao; Alan Pater; Tsuyoshi Iwasaka
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

9.  Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.

Authors:  Jerome F Sah; Sivaprakasam Balasubramanian; Richard L Eckert; Ellen A Rorke
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population.

Authors:  Julia C Stingl; Thomas Ettrich; Rainer Muche; Martina Wiedom; Jürgen Brockmöller; Angela Seeringer; Thomas Seufferlein
Journal:  BMC Cancer       Date:  2011-08-18       Impact factor: 4.430

View more
  5 in total

1.  FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells.

Authors:  Sridhar Muthusami; D S Prabakaran; Jae-Ran Yu; Woo-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-24       Impact factor: 4.553

Review 2.  Green Tea Epigallocatechin-3-Gallate Regulates Autophagy in Male and Female Reproductive Cancer.

Authors:  Sze Wan Hung; Yiran Li; Xiaoyan Chen; Kai On Chu; Yiwei Zhao; Yingyu Liu; Xi Guo; Gene Chi-Wai Man; Chi Chiu Wang
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

3.  (-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation.

Authors:  Jiangyan Wang; Yu'an Xie; Yan Feng; Litu Zhang; Xinping Huang; Xiaoyun Shen; Xiaoling Luo
Journal:  Int J Oncol       Date:  2015-02-03       Impact factor: 5.650

4.  Dissipation Pattern, Processing Factors, and Safety Evaluation for Dimethoate and Its Metabolite (Omethoate) in Tea (Camellia Sinensis).

Authors:  Rong Pan; Hong-Ping Chen; Ming-Lu Zhang; Qing-Hua Wang; Ying Jiang; Xin Liu
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

5.  Prognostic and predictive roles of microRNA‑411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer.

Authors:  Wei Wei; Cun Liu
Journal:  Mol Med Rep       Date:  2019-11-20       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.